Definium Therapeutics, Inc.

NasdaqGS:DFTX Stock Report

Market Cap: US$1.7b

Definium Therapeutics Management

Management criteria checks 2/4

Definium Therapeutics' CEO is Rob Barrow, appointed in Jun 2021, has a tenure of 4.58 years. total yearly compensation is $2.67M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $6.20M. The average tenure of the management team and the board of directors is 1.2 years and 4.3 years respectively.

Key information

Rob Barrow

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage23.36%
CEO tenure4.6yrs
CEO ownership0.4%
Management average tenure1.2yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14

Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges

Apr 21

MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call

Jan 29

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 04

Psychedelic Stocks: Focus On Their Cash

Aug 15

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Jun 05

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Apr 04

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Feb 02

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

May 23
Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Feb 07
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Oct 19

MindMed announces proposed public offering of common shares

Sep 27

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Sep 20

CEO Compensation Analysis

How has Rob Barrow's remuneration changed compared to Definium Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$168m

Jun 30 2025n/an/a

-US$115m

Mar 31 2025n/an/a

-US$78m

Dec 31 2024US$3mUS$624k

-US$109m

Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$102m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$599k

-US$96m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$75m

Mar 31 2023n/an/a

-US$63m

Dec 31 2022US$5mUS$672k

-US$57m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$98m

Dec 31 2021US$12mUS$350k

-US$93m

Compensation vs Market: Rob's total compensation ($USD2.67M) is below average for companies of similar size in the US market ($USD5.30M).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.

CEO

Rob Barrow (35 yo)

4.6yrs
Tenure
US$2,669,010
Compensation

Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Barrow
CEO & Director4.6yrsUS$2.67m0.37%
$ 6.2m
Mark Sullivan
Chief Legal Officer & Corporate Secretary2.8yrsUS$1.16m0.087%
$ 1.5m
Daniel Karlin
Chief Medical Officer4.9yrsUS$1.33m0.29%
$ 4.9m
Scott Freeman
Co-Founder & Clinical Advisorno dataUS$501.19kno data
Leonard Latchman
Co-Founderno datano datano data
Brandi Roberts
Chief Financial Officerless than a yearno datano data
Peter Mack
Senior Vice President of Pharmaceutical Development & Operations1yrno datano data
Beth Calitri
Vice President of Corporate Communicationsless than a yearno datano data
Stephanie Fagan
Chief Corporate Affairs Officer1.5yrsno datano data
Gregg Pratt
Chief Regulatory & Quality Assurance Officer1.2yrsno datano data
Matthew Wiley
Chief Commercial Officerless than a yearno datano data
1.2yrs
Average Tenure
51.5yo
Average Age

Experienced Management: DFTX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Robert Barrow
CEO & Director4.1yrsUS$2.67m0.37%
$ 6.2m
Carol Vallone
Independent Chairperson4.3yrsUS$195.03k0.017%
$ 283.7k
David Gryska
Independent Director2.6yrsUS$153.67k0.011%
$ 182.1k
Suzanne Bruhn
Independent Director3.4yrsUS$149.81k0.018%
$ 302.6k
Robert Malenka
Chair of Scientific Advisory Board4.8yrsno datano data
Robert Dworkin
Member of Scientific Advisory Board4.4yrsno datano data
Maurizio Fava
Member of Scientific Advisory Board4.6yrsno datano data
Andreas Krebs
Independent Vice Chairman4.3yrsUS$185.03k0.0040%
$ 66.7k
Roger Crystal
Independent Director3.4yrsUS$149.81k0.018%
$ 302.6k
Nzinga Harrison
Member of Scientific Advisory Board1.3yrsno datano data
Peter Bergethon
Member of Scientific Advisory Board4.6yrsno datano data
Maria Oquendo
Member of Scientific Advisory Board4.2yrsno datano data
4.3yrs
Average Tenure
67yo
Average Age

Experienced Board: DFTX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/22 10:55
End of Day Share Price 2026/01/22 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Definium Therapeutics, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Christopher ChenBaird
null nullBaird